Advances in application of transarterial chemoembolization combined with targeted therapy/immunotherapy in advanced hepatocellular carcinoma
10.3969/j.issn.1001-5256.2022.12.033
- VernacularTitle:经肝动脉化疗栓塞术联合靶向/免疫治疗在中晚期肝细胞癌中的应用进展
- Author:
Xiaohui ZHAO
1
;
Quanjun YAO
1
;
Hailiang LI
1
;
Hongtao HU
1
Author Information
1. Department of Minimally Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University & Cancer Hospital of Henan Province, Zhengzhou 450008, China
- Publication Type:Reviews
- Keywords:
Carcinoma, Hepatocellular;
Targeted Therapy;
Immunotherapy;
Chemoembolization, Therapeutic
- From:
Journal of Clinical Hepatology
2022;38(12):2855-2858
- CountryChina
- Language:Chinese
-
Abstract:
Most of the patients with hepatocellular carcinoma (HCC) in China are in the advanced stage at the time of diagnosis, and the treatment methods for HCC mainly include transarterial chemoembolization and systemic therapy. This article introduces the targeted drugs represented by sorafenib and lenvatinib, and the emergence of immunotherapy. Atezolizumab combined with bevacizumab has been approved as the first-line therapy for HCC, and meanwhile, studies on TACE combined with targeted therapy and/or immunotherapy have achieved a satisfactory treatment outcome, which brings better survival and prognosis for patients with advanced HCC. However, more studies are needed to solve the issues related to the prognosis of advanced HCC.
